Novakand Pharma AB (publ) (STO:NOVKAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.1400
+0.0130 (10.24%)
Jan 21, 2026, 5:29 PM CET
-86.41%
Market Cap15.39M
Revenue (ttm)n/a
Net Income (ttm)-51.90M
Shares Out121.19M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume573,659
Average Volume632,282
Open0.1252
Previous Close0.1270
Day's Range0.1252 - 0.1510
52-Week Range0.1210 - 2.2500
Beta1.10
RSI41.31
Earnings DateFeb 20, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. The com... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol NOVKAN
Full Company Profile

Financial Performance

Financial Statements